Coronavirus Scientific Advisory Board

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Nov. 1, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

Extracellular Nanoparticles Sourced From Another Species Reverses Biological Age of Rats by More Than 50%

Retrieved on: 
Wednesday, November 1, 2023
Rat, Ageing, Plasma, Stanford University, Human, Coronavirus Scientific Advisory Board, Exosome, Pet, Diabetes, Doctor of Philosophy, Nanoparticle, Research, Multimedia, Stunning, Dark Ages, Rest, Biostatistics, Biology, Animal, UCLA, DNA, Pharmaceutical industry, GeroScience, Genetics, E5

MOUNTAIN VIEW, Calif., Oct. 31, 2023 /PRNewswire/ -- In a groundbreaking research paper titled "Reversal of Biological Age in Multiple Rat Organs by Young Porcine Plasma Fraction" published in GeroScience, scientists have unveiled a remarkable breakthrough in the field of aging biology. A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days. E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.

Key Points: 
  • Peer Reviewed Publication: World's first demonstration of cross species epigenetic transfer that significantly reverses biological age by Scientists at Yuvan Research.
  • A therapeutic called E5 developed by Harold Katcher PhD and his colleagues was injected into old rats making them significantly younger within days.
  • E5 consists of nanoparticles of complex structure, including exosomes, from young plasma sourced from another species.
  • Upon final analysis by Horvath and his team, there was a remarkable 67.4% average reversal in the epigenetic age of treated elderly rats.

Think Bioscience Appoints Wendy Young, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023
Molecule, American Cancer Society, Genomics, Therapy, Scio Diamond Technology Corporation, GV (company), Wake Forest University, Medicinal chemistry, Research, Protein, Journal, Journal of Medicinal Chemistry, Senior, Princeton University, Celera Corporation, Memorial Sloan Kettering Cancer Center, Multiple sclerosis, Genentech, BTK, Chemistry, Patient, Coronavirus Scientific Advisory Board, Pharmaceutical industry, List of life sciences

BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young, Ph.D., to its Scientific Advisory Board. Dr. Young is a seasoned pharmaceutical professional with 30+ years of experience in small molecule research and development

Key Points: 
  • Think Bioscience brings on accomplished biotech executive and drug discovery veteran Wendy Young, Ph.D.
    BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young , Ph.D., to its Scientific Advisory Board.
  • "We are excited to leverage her deep expertise to build Think into an industry-leading research and development organization."
  • Dr. Young currently serves as a director and/or scientific advisor to several biotech companies and is an advisor at Google Ventures.
  • "I'm excited by the elegance of the Think Bioscience platform, which can discover new functional binding sites and access novel chemical matter.

Stan Lapidus Joins Calviri's Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023
American Institute, Cervical cancer, Vaccine, History, Human, Medicine, Colorectal cancer, Invention, MD, Biology, Entrepreneurship, Liquid-based cytology, Exact Sciences (company), Animal, Conditional sentence, American Institute for Medical and Biological Engineering, Cancer, PAP, Exact sciences, SAB, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Medical imaging

PHOENIX, Oct. 30, 2023 /PRNewswire/ -- Calviri, Inc.— a leading biotech developer of promising new vaccines and diagnostics against cancer - today announced that Stan Lapidus, the founder of Cytyc Corporation and EXACT Sciences, has been elected to join Calviri's Scientific Advisory Board.

Key Points: 
  • PHOENIX, Oct. 30, 2023 /PRNewswire/ -- Calviri, Inc.— a leading biotech developer of promising new vaccines and diagnostics against cancer - today announced that Stan Lapidus, the founder of Cytyc Corporation and EXACT Sciences, has been elected to join Calviri's Scientific Advisory Board.
  • Lapidus will bring decades of experience in medical invention and entrepreneurship, and a decades-long track record in the development and execution of platforms and screenings for multiple cancers.
  • ThinPrep has been shown to be 65% more effective than other tests at detecting cervical cancer and precancerous lesions.
  • "Stan is one of the leading experts on cancer diagnostics with a long and distinguished history in this area.

Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer

Retrieved on: 
Monday, October 30, 2023
IPO, Janssen, SVP, MD, Respiratory system, Doctor of Philosophy, Coronavirus Scientific Advisory Board, ARS, Record, Immune tolerance, Health, Infection, Infectious Disease Clinics of North America, Therapy, Wolfgang Amadeus Mozart, Management, Vaccine

SEATTLE, Oct. 30, 2023 /PRNewswire/ -- Mozart Therapeutics, the leading developer of CD8 Treg modulators for the treatment of autoimmune and inflammatory disease, today announced the expansion of its executive leadership team with the appointments of Jason Chien, MD, as Chief Medical Officer, and Russ Hawkinson as Chief Financial Officer. Additionally, Gerald Nepom, MD, PhD, emeritus faculty member of the Benaroya Research Institute Center for Interventional Immunology and former Director of the Immune Tolerance Network, has joined Mozart's Scientific Advisory Board.

Key Points: 
  • SEATTLE, Oct. 30, 2023 /PRNewswire/ -- Mozart Therapeutics , the leading developer of CD8 Treg modulators for the treatment of autoimmune and inflammatory disease, today announced the expansion of its executive leadership team with the appointments of Jason Chien, MD, as Chief Medical Officer, and Russ Hawkinson as Chief Financial Officer.
  • "Jason Chien and Russ Hawkinson are industry veterans with established track records and a wealth of strategic and operating experience.
  • Dr. Chien brings nearly 30 years of experience in immunology and infectious diseases from his work in academia, healthcare, and the biopharmaceutical industry.
  • Mr. Hawkinson brings over 20 years of experience guiding financial strategy in the life science industry.

Avantor® Reports Third Quarter 2023 Results

Retrieved on: 
Friday, October 27, 2023
Adjustment, Education, NYSE, Government, AVTR, Avantor, EBITDA, GAAP, Environment, EPS, COVID-19, Investment, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Bookkeeping, Liquor, Commercial property

"We delivered third quarter business results in line with our guidance for the quarter and end market conditions remained stable, as anticipated.

Key Points: 
  • "We delivered third quarter business results in line with our guidance for the quarter and end market conditions remained stable, as anticipated.
  • For the three months ended September 30, 2023, net sales were $1.72 billion, a decrease of 7.3% compared to the third quarter of 2022.
  • Adjusted net leverage was 3.9X as of September 30, 2023, and we have repaid more than $650 million of total debt in the first three quarters of 2023.
  • We will host a conference call to discuss our results today, October 27, 2023, at 8:00 a.m. Eastern Time.

Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • “We need more effective treatments to improve the outcomes for patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma,” said Dr. Liedtke.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.

Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, October 26, 2023
Multiple myeloma, American Society of Clinical Oncology, American Society of Hematology, Clinical Cancer Research, MD–PhD, Coronavirus Scientific Advisory Board, Albert Einstein College of Medicine, MD, Harry Oppenheimer Fellowship Award, Stanford Department of Electrical Engineering, SWOG, Stanford University Medical Center, Society, Memorial, International Society, Patient, ASCO, Nursing, Amyloidosis, Hematology, Hannover Medical School

LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Dr. Michaela Liedtke has joined the Nexcella Scientific Advisory Board.
  • Dr. Liedtke brings decades of experience in hematology/oncology clinical trials, clinical trial design, and thought leadership to Nexcella.
  • We are excited to be working with Dr. Liedtke.”
    Dr. Liedtke is the Stanford University Medicine Cancer Center Program Lead, Hematology; Co-Director, Stanford Amyloid Center; Medical Director, Stanford Adolescent and Young Adult Program; and Member Leukemia Committee, Southwest Oncology Group.
  • Dr. Liedtke completed her fellowship at Stanford University Medical Center and Memorial Sloan-Kettering Cancer Center, residency at the Albert Einstein College of Medicine, and received her medical degree from Medizinische Hochschule Hannover.

Hydromer Inc. Announces Formation of its Scientific Advisory Board with the Appointment of its First Member Eric Becktel

Retrieved on: 
Tuesday, October 24, 2023
Knowledge, Applied science, Sale, OTC, Augsburg University of Applied Sciences, Hellenic American University, Brown University Graduate School, Learning, Growth, Hellenic, American University, Bachelor of Applied Science, Hand, Physics, Technical University of Munich, Institute of technology, Coronavirus Scientific Advisory Board, Management, Nursing, Hydromancy, Priceline, Audi, Porsche, Chemistry

CONCORD, NC, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hydromer, Inc (OTC: HYDI), is thrilled to announce the formation of the Company's first Scientific Advisory Board and proudly introduce its inaugural member, Mr. Eric Becktel.

Key Points: 
  • CONCORD, NC, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hydromer, Inc (OTC: HYDI), is thrilled to announce the formation of the Company's first Scientific Advisory Board and proudly introduce its inaugural member, Mr. Eric Becktel.
  • Now, we are excited to welcome him aboard to offer his unparalleled expertise formally as a member of our Scientific Advisory Board.
  • "We are excited to announce the formation of our Scientific Advisory Board and welcome Eric Becktel as its inaugural member," said Mike Torti, CEO.
  • As we embark on a new chapter, the formation of our Scientific Advisory Board marks a significant milestone in our journey.

Former U.S. Commissioner of Food and Drug Administration Stephen M. Hahn, M.D. Appointed to Alpha Tau Advisory Board

Retrieved on: 
Tuesday, October 24, 2023
Radiation, FDA, Food, Therapy, Prostate Cancer Foundation, Flagship Pioneering, Head, Monroe Dunaway Anderson, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Restart, Partnership, Immunotherapy, University, Squamous-cell carcinoma, MD Anderson Cancer Center, Alpha, Cancer, Patient, Glioblastoma, Alpha Sigma Tau, Neck, Coronavirus Scientific Advisory Board, Pharmaceutical industry

JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.

Key Points: 
  • JERUSALEM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today that Stephen M. Hahn, M.D., former commissioner of the U.S. Food and Drug Administration (“FDA”), has joined its Scientific Advisory Board.
  • “I am pleased to welcome Dr. Hahn to the Alpha Tau Scientific Advisory Board at an ideal time in the Company’s growth trajectory,” said Company CEO Uzi Sofer.
  • He previously served as FDA Commissioner from 2019 to 2021, overseeing regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
  • “I have been watching Alpha Tau’s development with excitement for quite some time,” said Dr. Hahn.